Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Cross screening panel
Assay data:1 Tested
SummaryRelated BioAssays by Target
Safety47 Scan (DiscoverX - Eurofins)
Adrenergic alpha1A Eurofins Panlabs panel
ALPHA1AH_ANTAG Eurofins SafetyScreen44 (BI)
ALPHA1A(H)AGON Eurofins SafetyScreen44 (BI)
ALPHA1A(H)ANTAG Eurofins SafetyScreen44 (BI)
Binding affinity towards human ADRA1A in an in vitro assay with cellular components (NIBR assay) measured by scintillation proximity assay
Assay data:49 Active, 29 Activity ≤ 1 µM, 231 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Antagonist activity at human ADRA1A in an in vitro cell-based assay measured by fluorescence spectroscopy
Assay data:117 Active, 53 Activity ≤ 1 µM, 881 Tested
Binding affinity towards human ADRA1A in an in vitro assay (CRO assay) measured by scintillation counting
Assay data:9 Active, 5 Activity ≤ 1 µM, 104 Tested
Assay data:150 Active, 65 Activity ≤ 1 µM, 699 Tested
Assay data:99 Active, 56 Activity ≤ 1 µM, 800 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on